Divi's Laboratories

Strong custom synthesis growth, improving margins and projects nearing commercialisation support Divi's Labs' outlook, though elevated valuations remain a concern for analysts

Updated On: 09 Nov 2026 | 10:05 PM IST

Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said. Revenue from operations rose 35.39 per cent to Rs 3,676 crore during the second quarter of FY27 from Rs 2,715 crore a year earlier, it said. Its total expenses rose to Rs 2,265 crore in the period under review from Rs 1,948 crore a year ago, it added. The company's net profit for the first half of the current fiscal year, however, declined 35.39 per cent to Rs 2,029 crore from Rs 2,568 crore in the year-ago period, the filing added.

Updated On: 07 Nov 2026 | 3:11 PM IST

Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside

Updated On: 03 Aug 2026 | 10:44 PM IST

Q1FY27 company results: Firms including Aarti Surfactants, Aditya Birla Lifestyle Brands, APL Apollo Tubes, and Utkarsh Small Finance Bank are also to release their April-June earnings today

Updated On: 01 Aug 2026 | 8:16 AM IST

The Hyderabad-based company's consolidated net profit marginally fell to ₹583 crore ($64.31 million) in the quarter ended December 31, from ₹589 crore a year earlier

Updated On: 11 Feb 2026 | 2:46 PM IST

Meanwhile, eight companies dropped off the list: among them were IndusInd Bank, Indian Overseas Bank, Canara Bank, Dr Reddy's Laboratories, Adani Total Gas, and Zydus Lifesciences

Updated On: 06 Apr 2025 | 10:09 PM IST

Its revenue from operations climbed 25 per cent to Rs 2,319 crore during the quarter, roughly in line with analysts' estimate of Rs 2,343 crore

Updated On: 03 Feb 2025 | 2:34 PM IST

Stocks to watch on May 27: Divi's Labs net profit soared by an impressive 67.6 per cent year-on-year (YoY), reaching Rs 538 crore compared to Rs 321 crore

Updated On: 27 May 2024 | 7:35 AM IST

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Updated On: 06 Nov 2023 | 1:35 PM IST

Revenue of the contract research and manufacturing services player was down 21 per cent y-o-y

Updated On: 18 Aug 2023 | 9:52 PM IST

Brokerages expect a sequential improvement in margins

Updated On: 13 Apr 2023 | 11:54 PM IST

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

Updated On: 04 Feb 2023 | 12:21 AM IST

In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall in revenue

Updated On: 03 Feb 2023 | 2:26 PM IST

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Updated On: 09 Nov 2022 | 12:05 AM IST

Divi's Laboratories on Monday said its consolidated net profit declined by 18 per cent to Rs 494 crore in the second quarter of the current financial year. The drug firm had reported a net profit of Rs 606 crore in the July-September period of last fiscal. Revenue from operations declined to Rs 1,854 crore in the September quarter as against Rs 1,987 crore in the year-ago period. Shares of the company on Monday ended 8.63 per cent at Rs 3,422 apiece on the BSE.

Updated On: 07 Nov 2022 | 4:39 PM IST

Brokerages give add, accumulate or buy ratings given the company's growth and track record

Updated On: 18 Aug 2022 | 11:39 PM IST

The analysis is based on a common sample of 76 companies from the Nifty 100 index

Updated On: 26 May 2022 | 12:26 PM IST

Pfizer's oral Covid drug, weak sales of generics, and valuations may cap upsides

Updated On: 16 Nov 2021 | 10:38 PM IST

Supply of Molnupiravir to Merck was a key near-term trigger for the stock

Updated On: 08 Nov 2021 | 6:13 PM IST

Revenue growth prospects, however, remain strong driven by multiple factors

Updated On: 10 Aug 2021 | 12:55 AM IST